Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
ABX464 is being tested for numerous indications, including ulcerative colitis.
Stakeholders are hoping ABX464 continues to perform well in clinical trials in treating patients with moderate-to-severe ulcerative colitis.
Recently, a 16 week phase 2b trial concluded testing different doses of the drug against a placebo for ulcerative colitis patients.
Researchers from Abivax, tested 25, 50, and 100 mg of ABX464 in 130 study centers in the US, Canada, and 15 European countries involving more than 800 patients across different indications, including ulcerative colitis.
Each patient in the study was offered the opportunity to continue in an open-label maintenance study, in which patients are treated with 50 mg of once-daily oral ABX464.
And while the feeling is the treatment is positive, top-line data is expected to be available in May and a phase 3 clinical trial for ulcerative colitis patients could begin by the end of the year.
In an interview with HCPLive®, Hartmut J. Ehrlich, MD, CEO of Abivax and Philippe Pouletty, MD, chairman of the board of directors at Abivax, see the signs that ABX464 is going to be a major factor in ulcerative colitis treatment.
The researchers said while it is unlikely the treatment would move to the first option for ulcerative colitis, it is very likely ABX464 would be considered a second or third option for patients.